Anke van den Berg
prof. dr.
I work as a clinical molecular biologist in the department of Pathology. In this function I supervise and implement advanced molecular diagnostic techniques. Within my research line, I focus on the molecular pathogenesis of B-cell Hodgkin and non-Hodgkin lymphoma. The specific fields of interest are genomic aberrations, genetic susceptibility, and the role of small and long noncoding RNAs. I have several international collaborations and am PI and co-PI in various projects.
RT-PCR and immunohistochemical evaluation of sentinel lymph nodes after in vivo mapping with Patent Blue V in colon cancer patients
Published in: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
Access to document
10.1080/00365520600554469
Objective. Lymph node status is the most important predictive factor in the treatment of colorectal cancer. As sentinel lymph node ( SLN) biopsy might upstage stage II colon cancer, it could have therapeutic consequences in the future. We investigated the feasibility of in vivo SLN detection with Patent Blue V dye and evaluated nodal microstaging and ultrastaging using cytokeratin immunohistochemistry and reverse transcriptase-polymerase chain reaction ( RTPCR). Material and methods. In 30 consecutive patients operated on for colon cancer, subserosal injection with Patent Blue dye was used for...
Wendy Kelder, Anke Van den Berg, Judith Van der Leij, Wim Bleeker, Anton T. M. G. Tiebosch, Joris K. Grond, Peter C. Baas, John Th. Plukker
Gene expression analysis of dendritic/Langerhans cells and Langerhans cell histiocytosis
Published in: The Journal of Pathology
Access to document
10.1002/path.2003
Langerhans cell histiocytosis (LCH) is a neoplastic disorder that results in clonal proliferation of cells with a Langerhans cell (LQ phenotype. The pathogenesis of LCH is still poorly understood. In the present study, serial analysis of gene expression (SAGE) was applied to LCs generated from umbilical cord blood CD34+ progenitor cells to identify LC-specific genes and the expression of these genes in LCH was investigated. Besides the expression of several genes known to be highly expressed in LCs and LCH such as CD1a, LYZ, and CD207, high expression...
Renata Rust, J. Kluiver, Lydia Visser, G. Harms, T. Blokzijl, W.A. Kamps, Sibrand Poppema, Anke van den Berg
Upregulation of ADAM19 in chronic allograft nephropathy
Published in: American Journal of Transplantation
Access to document
10.1111/j.1600-6143.2006.01384.x
ADAM19 (a disintegrin and metalloproteinase 19) is involved in cell-cell and cell-matrix interactions and tumor necrosis factor (TNF)-alpha shedding. We studied ADAM19 in chronic allograft nephropathy (CAN) nephrectomies and in normal human kidneys. Reverse transcriptase (RT) PCR revealed an upregulation of ADAM19 mRNA in CAN when compared with control kidneys (p = 0.002). Using RNA in situ hybridization (ISH), we detected moderate ADAM19 mRNA expression in vascular smooth muscle cells (SMCs) and distal tubuli of control kidneys. In CAN, massive ADAM19 expression was detected in SMCs, distal tubuli,...
WBWH Melenhorst, MC van den Heuvel, CA Stegeman, J van der Leij, S Huitema, Anke van den Berg, H van Goor
BCL6 alternative breakpoint region break and homozygous deletion of 17q24 in the nodular lymphocyte predominance type of Hodgkin’s lymphoma-derived cell line DEV
Published in: Human Pathology
Access to document
10.1016/j.humpath.2006.01.018
DEV is the only cell line derived from nodular lymphocyte predominance type of Hodgkin’s lymphoma (NLPHL); however, a comprehensive report about the genetic and immunophenotypic profile of this unique cell line is lacking. We analyzed DEV with respect to immunophenotype and genetic aberrations. The immunostaining revealed positivity for CD45, CD20, CD22, CD79a, IgA2, CD80, CD86, CD74, and BCL6. Cytogenetically, DEV has complex chromosome 3 translocations involving chromosomes 7, 14, and 22. A detailed analysis of the 3q27 breakpoint of the der(3)t(3;14)(p14;q32)t(3;22)(q27;q11.2) revealed a break in the BCL6 alternative...
Cigdem Atayar, K Kok, J. Kluiver, Annigje Bosga - Bouwer, Eva van den Berg, P. Van der Vlies, T. Blokzijl, G. Harms, I. Davelaar, B Sikkema-raddatz, J.I. Martin-Subero, R. Siebert, Sibrand Poppema, Anke van den Berg
Molecular, cytogenetic, and immunophenotypic characterization of follicular lymphoma grade 3B; a separate entity or part of the spectrum of diffuse large B-cell lymphoma or follicular lymphoma?
Published in: Human Pathology
Access to document
10.1016/j.humpath.2005.12.005
We studied a histological homogeneous group of 29 cases with the diagnosis of follicular lymphoma (FL) grade 313 (FL3Bs). In a previous study, we subdivided this group in 3 subgroups based on (1) aberrations of the 3q27 region, (2) lack of 3q27 and t(14; 18), and (3) the presence of a t(14; 18). In this study, we further characterized the FL3B lymphomas that are currently part of the spectrum of FL in the WHO classification, taking into account other cytogenetical aberrations, immunohistochemistry for P53, bcl2, bcl6, and CD10,...
A.G. Bosga-Bouwer, Anke van den Berg, E. Haralambieva, Doetje de Jong, Ronald Boonstra, P.M. Kluin, Eva van den Berg, Sibrand Poppema